SI9400085A - Vaccine compositions comprising antigenic polypeptide and 3d-mpl, useful in preventing infection with influenza - Google Patents

Vaccine compositions comprising antigenic polypeptide and 3d-mpl, useful in preventing infection with influenza Download PDF

Info

Publication number
SI9400085A
SI9400085A SI9400085A SI9400085A SI9400085A SI 9400085 A SI9400085 A SI 9400085A SI 9400085 A SI9400085 A SI 9400085A SI 9400085 A SI9400085 A SI 9400085A SI 9400085 A SI9400085 A SI 9400085A
Authority
SI
Slovenia
Prior art keywords
mpl
vaccine composition
protein
vaccine
composition according
Prior art date
Application number
SI9400085A
Other languages
English (en)
Slovenian (sl)
Inventor
Susan Dillon
Hirotoshi Nishikawa
Paul Dal Monte
Robert J Gyurick
Nathalie Marie- Garcon-Johnson
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Biolog filed Critical Smithkline Beecham Corp
Publication of SI9400085A publication Critical patent/SI9400085A/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI9400085A 1993-02-19 1994-02-18 Vaccine compositions comprising antigenic polypeptide and 3d-mpl, useful in preventing infection with influenza SI9400085A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2153593A 1993-02-19 1993-02-19
US11575093A 1993-09-01 1993-09-01

Publications (1)

Publication Number Publication Date
SI9400085A true SI9400085A (en) 1994-09-30

Family

ID=26694802

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9400085A SI9400085A (en) 1993-02-19 1994-02-18 Vaccine compositions comprising antigenic polypeptide and 3d-mpl, useful in preventing infection with influenza

Country Status (9)

Country Link
EP (1) EP0684838A1 (es)
AP (1) AP431A (es)
AU (1) AU6141094A (es)
CA (1) CA2156525A1 (es)
IL (1) IL108681A0 (es)
MA (1) MA23118A1 (es)
MX (1) MX9401225A (es)
SI (1) SI9400085A (es)
WO (1) WO1994019013A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
SG48309A1 (en) * 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6261573B1 (en) * 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
DE60239594D1 (de) * 2001-02-23 2011-05-12 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
AR032575A1 (es) * 2001-02-23 2003-11-12 Smithkline Beecham Biolog Uso de una preparacion antigenica de gripe para la fabricacion de una vacuna intradermica de la gripe y estuche farmaceutico que comprende dicha vacuna
GB2386072A (en) * 2001-04-27 2003-09-10 Becton Dickinson Co Novel vaccine
RS51721B (en) 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Reduction of potential iatrogenic risks associated with influenza vaccines
CA2586690A1 (en) 2004-11-03 2006-06-15 Novartis Vaccines And Diagnostics, Inc. Influenza vaccination
HUE027837T2 (en) 2005-03-23 2016-11-28 Glaxosmithkline Biologicals Sa Adjuvant use of influenza virus and oil-in-water emulsion to induce CD4 T-cell and / or enhanced B-cell cellular response
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
BRPI0721393B8 (pt) * 2007-03-22 2022-09-06 Fund Butantan método para obter lipídeo a monofosforilado da bordetella pertussis como um subproduto da produção de vacina celular contra coqueluche
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
EP2268309B1 (en) * 2008-03-18 2015-01-21 Novartis AG Improvements in preparation of influenza virus vaccine antigens
CA2812135A1 (en) 2010-09-07 2012-03-15 Novartis Ag Generic assays for detection of mammalian reovirus
SG11201607404PA (en) * 2014-03-25 2016-10-28 Government Of The Us Secretary Of The Army Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines
EP3820510A4 (en) 2018-07-10 2022-05-04 Seqirus Pty Ltd REMOVAL OF AGGLOMERATES
CN112361796A (zh) * 2020-11-13 2021-02-12 安徽省天长市周氏羊业有限公司 一种秸秆回收储存前破碎干燥装置
CN114989269B (zh) * 2022-06-30 2023-09-19 天康制药股份有限公司 一种牛赤羽免疫原性抗原及疫苗

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5230899A (en) * 1985-08-07 1993-07-27 Smithkline Beecham Corporation Methods and compositions for making liposomes
IL79114A (en) * 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
AU631377B2 (en) * 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
AU640348B2 (en) * 1988-08-31 1993-08-26 Smithkline Beecham Corporation Vaccinal Polypeptides
DK425789A (da) * 1988-08-31 1990-03-01 Smithkline Beecham Corp Vaccinale polypeptider
AU654970B2 (en) * 1990-09-28 1994-12-01 Smithkline Beecham Biologicals (Sa) Derivatives of gp160 and vaccines based on gp160 or a derivative thereof, containing an adjuvant
WO1992011291A1 (en) * 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen
FR2671974A1 (fr) * 1991-01-24 1992-07-31 Pasteur Merieux Serums Vacc Composition vaccinale contre la grippe, a effet synergique, contenant comme additif du core de virus grippal.
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
ES2143716T3 (es) * 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.

Also Published As

Publication number Publication date
AU6141094A (en) 1994-09-14
MA23118A1 (fr) 1994-10-01
MX9401225A (es) 1994-08-31
EP0684838A1 (en) 1995-12-06
CA2156525A1 (en) 1994-09-01
AP431A (en) 1995-11-15
WO1994019013A1 (en) 1994-09-01
IL108681A0 (en) 1994-05-30
AP9400621A0 (en) 1994-04-30

Similar Documents

Publication Publication Date Title
SI9400085A (en) Vaccine compositions comprising antigenic polypeptide and 3d-mpl, useful in preventing infection with influenza
ES2337901T3 (es) Vacuna de subunidad contra infeccion por el virus respiratorio sincicial.
US10030053B2 (en) Immunogenic compositions and methods of use thereof
ES2307494T3 (es) Vacuna del virus de la gripe inactivo para su administracion via nasalu oral.
JP5796011B2 (ja) ワクチン
CN111375055B (zh) 一种2019-nCoV亚单位疫苗组合物及其免疫方法
JP2016128457A (ja) 組換えrsv抗原
BRPI0815008B1 (pt) vacinas multiméricas com múltiplos epítopos contra influenza
TWI329130B (en) Functionally reconstituted viral membranes containing adjuvant
CA2169297C (en) Protein- or peptide-cochleate vaccines and methods of immunizing using the same
HU226214B1 (en) Vaccines with an ltb adjuvant
JP2018172417A (ja) 乳児においてrsv及び百日咳菌に対する免疫応答を惹起するための方法
US20230416311A1 (en) Influenza vaccines
BR112012022059B1 (pt) Vacina de mucosa produtora de uma iga de mucosa antígenoespecífica e igg do sangue e método para produzir uma vacina de mucosa
JPH08506592A (ja) 3−o−脱アシル化モノホスホリル脂質A含有のインフルエンザワクチン組成物
JP2015525794A (ja) 乳児においてrsv及び百日咳菌に対する免疫応答を惹起するための方法
ES2338382T3 (es) Vacuna intranasal antigripal basada en virosomas.
EP0546036A1 (en) Vaccines.
WO2016039620A2 (en) Respiratory syncytial virus virosomes
PL206260B1 (pl) Immunogenna kompozycja liposomowa, jej zastosowanie, sposoby jej wytwarzania i kompozycja szczepionki